Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA.
Mol Imaging Biol. 2013 Feb;15(1):97-105. doi: 10.1007/s11307-012-0572-0.
This systematic review and meta-analysis aimed to quantify the diagnostic performance of pancreatic venous sampling (PVS), selective pancreatic arterial calcium stimulation with hepatic venous sampling (ASVS), and (18)F-DOPA positron emission tomography (PET) in diagnosing and localizing focal congenital hyperinsulinism (CHI).
This systematic review and meta-analysis was conducted according to the PRISMA statement. PubMed, EMBASE, SCOPUS and Web of Science electronic databases were systematically searched from their inception to November 1, 2011. Using predefined inclusion and exclusion criteria, two blinded reviewers selected articles. Critical appraisal ranked the retrieved articles according to relevance and validity by means of the QUADAS-2 criteria. Pooled data of homogeneous study results estimated the sensitivity, specificity, likelihood ratios and diagnostic odds ratio (DOR).
(18)F-DOPA PET was superior in distinguishing focal from diffuse CHI (summary DOR, 73.2) compared to PVS (summary DOR, 23.5) and ASVS (summary DOR, 4.3). Furthermore, it localized focal CHI in the pancreas more accurately than PVS and ASVS (pooled accuracy, 0.82 vs. 0.76, and 0.64, respectively). Important limitations comprised the inclusion of studies with small sample sizes, high probability of bias and heterogeneity among their results. Studies with small sample sizes and high probability of bias tended to overestimate the diagnostic accuracy.
This systematic review and meta-analysis found evidence for the superiority of (18)F-DOPA PET in diagnosing and localizing focal CHI in patients requiring surgery for this disease.
本系统评价和荟萃分析旨在定量评估胰腺静脉采样(PVS)、选择性胰腺动脉钙刺激联合肝静脉采样(ASVS)以及 18F-DOPA 正电子发射断层扫描(PET)在诊断和定位局灶性先天性高胰岛素血症(CHI)中的诊断性能。
本系统评价和荟萃分析根据 PRISMA 声明进行。通过系统检索 PubMed、EMBASE、SCOPUS 和 Web of Science 电子数据库,检索时间截至 2011 年 11 月 1 日。通过预定义的纳入和排除标准,两名盲审员筛选文章。采用 QUADAS-2 标准,通过相关性和有效性对检索到的文章进行关键评估和评分。对同质研究结果进行汇总数据评估,估计敏感性、特异性、似然比和诊断比值比(DOR)。
与 PVS(汇总 DOR,23.5)和 ASVS(汇总 DOR,4.3)相比,18F-DOPA PET 在区分局灶性和弥漫性 CHI 方面具有更高的优势(汇总 DOR,73.2)。此外,它比 PVS 和 ASVS 更准确地定位胰腺中的局灶性 CHI(汇总准确性,0.82 比 0.76 和 0.64)。重要的局限性包括纳入的研究样本量小、存在高度偏倚和结果异质性。样本量小和存在高度偏倚的研究往往会高估诊断准确性。
本系统评价和荟萃分析发现,在需要手术治疗的局灶性 CHI 患者中,18F-DOPA PET 在诊断和定位局灶性 CHI 方面具有优势。